Company / Revenue per Share
Vistagen Therapeutics, Inc. Revenue per Share History
FY2011-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
-
FY2021
5-year range
$0.00 / $0.25
FY2017-FY2021
Trend
-100.0%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Remained stable around $0.00 over the past 4 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, revenue per share decreased 100.0% year-over-year.
- Peak revenue per share was recorded in FY2011.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $0.00 | -100.0% |
| FY2018 | $0.25 | - |
| FY2017 | $0.00 | -100.0% |
| FY2014 | $0.01 | -90.8% |
| FY2012 | $0.12 | -69.4% |
| FY2011 | $0.40 | - |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026